Evaluation of Lu AF28996 in the Treatment of Parkinson's Disease in Affected Patients

The primary objective of the study titled "Lu AF28996 in Patients With **Parkinson's Disease**" is not explicitly stated in the provided data. However, the study is focused on evaluating the effects of Lu AF28996 in individuals diagnosed with Parkinson's Disease. This is clinically relevant as Parkinson's Disease is a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, and there is a continuous need for effective therapeutic interventions to manage these symptoms and improve patient quality of life.

The clinical trial involves a total of **26 participants** diagnosed with **Parkinson's Disease**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, and there are no specific lifestyle considerations such as diet or physical activity mentioned. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of a new investigational product in patients diagnosed with **Parkinson's Disease**. This study is a Phase 3, randomized, double-blind, controlled trial, which aims to provide robust data on the therapeutic potential of the investigational product. The trial is expected to commence recruitment on May 17, 2024, and is projected to conclude by September 10, 2025. Participants will be randomly assigned to either the investigational product group or a control group, ensuring that neither the participants nor the investigators are aware of the group assignments, thus maintaining the integrity of the double-blind design.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following successful screening, participants will undergo a series of follow-up visits at regular intervals. These visits are designed to monitor the participants' health, assess the efficacy of the treatment, and record any adverse events. The end-of-study visit marks the conclusion of the participant's involvement in the trial, where final assessments are conducted to gather comprehensive data on the treatment's impact.

The expected duration of participant involvement in the trial is approximately 16 months, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent by the participant, or any other medical reasons deemed necessary by the investigators. The trial's methodology and design are structured to ensure the collection of high-quality data while prioritizing the safety and well-being of the participants throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information on the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 17, 2024, with an estimated completion date of September 10, 2025. The efficacy assessment will be conducted in accordance with the trial's protocol, which is aligned with the standards for Phase 3 clinical trials. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and schedule for measuring, collecting, and analyzing these parameters, are not detailed in the provided data. The trial will adhere to rigorous scientific and ethical standards to ensure the validity and reliability of the efficacy outcomes.